![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Switching to Dolutegravir/Lamivudine (DTG/3TC) Is Non-inferior to Continuing Tenofovir Alafenamide (TAF)-Based Regimens at Week 196: TANGO Subgroup Analyses
|
|
|
IAS 2023 jut 25
Don E. Smith,1 Jean-Pierre Routy,2 Stefan Scholten,3 Julián Olalla Sierra,4 Mounir Ait-Khaled,5 Ruolan Wang,6 Parminder Saggu,7 Riya Moodley,5 Bryn Jones5
1Albion Centre, Sydney, Australia; 2McGill University Health Centre, Montreal, QC, Canada; 3Praxis Hohenstaufenring, Cologne, Germany; 4Hospital Costa del Sol, Marbella, Spain; 5ViiV Healthcare, Brentford, UK; 6ViiV Healthcare, Durham, NC, USA; 7GSK, Brentford, UK
![0726231](../images/072623/072623-2/0726231.gif)
![0726232](../images/072623/072623-2/0726232.gif)
![0726233](../images/072623/072623-2/0726233.gif)
![0726234](../images/072623/072623-2/0726234.gif)
![0726235](../images/072623/072623-2/0726235.gif)
![0726236](../images/072623/072623-2/0726236.gif)
![0726237](../images/072623/072623-2/0726237.gif)
![0726238](../images/072623/072623-2/0726238.gif)
![0726239](../images/072623/072623-2/0726239.gif)
![07262310](../images/072623/072623-2/07262310.gif)
![07262311](../images/072623/072623-2/07262311.gif)
![07262312](../images/072623/072623-2/07262312.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|